Cisplatin in Combination with Apigenin Inhibits Human Osteosarcoma Cells Proliferation by Promoting Osteogenic Differentiation: A Mechanistic Insight

ABSTRACT

Background: Osteosarcoma, the predominant primary bone cancer in the pediatric and adolescent population globally, exhibits a relatively low annual incidence but contributes significantly to morbidity and mortality. Objectives: The current study aims to explore the impact of cisplatin, apigenin, and their combination on human osteosarcoma cell line (MG-63) osteosarcoma cells, given the challenges in clinical treatment such as chemotherapy’s adverse effects, resistance development, and relapses. Materials and Methods: Cytotoxicity assessment using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was conducted for cisplatin, apigenin, and their combination. Apoptotic potential was evaluated through ethidium bromide (EtBr)/acridine orange (AO) dual staining for the combination treatment. Reactive oxygen species (ROS) production and cell cycle arrest were analyzed posttreatment with the cisplatin + apigenin combination using 2′-7′-dichlorodihydrofluorescein diacetate (DCF-DA) staining and fluorescence-activated cell sorting (FACS) analysis, respectively. Proapoptotic and antiapoptotic gene expression was assessed via quantitative polymerase chain reaction (qPCR) analysis. Additionally, messenger ribonucleic acid (mRNA) and protein expression of B-cell-specific Moloney murine leukemia virus integration site 1 (BMIL1) were analyzed in both untreated and cisplatin + apigenin treated cells. Enzymelinked immunosorbent assay (ELISA) analysis was performed for p16INK4a, E-cadherin, and Notch1. Results: Results indicated that the combination treatment significantly inhibited MG-63 cell proliferation compared to individual treatments. Enhanced apoptosis and ROS production were observed in the combination treatment, along with cell cycle arrest at the subG0-G1 phase. Furthermore, the combination downregulated BMIL1 and Bcl-2 expression while upregulating mRNA expression of Bax, Caspase-3, Caspase-9, Apaf-1, and p53. Gene expression results corroborated BMIL1 downregulation in the combination treatment. Additionally, protein levels of p16INK4a and E-cadherin were significantly decreased in the combination treatment compared to individual treatments and untreated control. Conclusions: In conclusion, cisplatin and apigenin combination exhibited superior efficacy against osteosarcoma.

KEYWORDS

• MG-63
• osteosarcoma
• apigenin
• cisplatin
• combination
• apoptosis

Showing references and in-text citations exactly as published.

• DOI10.1177/09731296241299496Copy

RELATED ARTICLES

Matched on section and article type within this issue of Pharmacogn. Mag..

• Article · VOLUME 21, ISSUE 3Bioflavonoid Tangeretin regulates RANK/RANKL/OPG Signaling Proteins via Stimulating Estrogenic Activity in Ovariectomized RatsWeike Tian, Wei Zhang, Li Chen, Junlei Liao, Xuesong Yang · pp. 1001–1012Original Research ArticleSame type: Article
• Article · VOLUME 21, ISSUE 3PhcogMag 21 3 1013Yanhong Zhang, Yanlong He · pp. 1013–1021Original Research ArticleSame type: Article
• Article · VOLUME 21, ISSUE 3Rosmanol Effectively Prevents Diethylnitrosamine-induced Hepatocellular Carcinoma in Rats by Regulating the PI3K/Akt Signaling PathwayWei Cao, Qi Liu, Ying Wang, Lianfeng Chen · pp. 1022–1033Original Research ArticleSame type: Article
• Article · VOLUME 21, ISSUE 3Liquiritin Promotes Vasodilation Effects by Activating the Kv and KATP Channels in the Isolated Rat Thoracic AortaMengXue Ma, YouLan Che, Xin Yang, Zhi Wang, Ya Wen Bai, Yang Yu, QingBin Xu, Ru Zhou · pp. 1034–1042Original Research ArticleSame type: Article